文献速递前列腺癌

Navigate治疗决策辅助工具用于前列腺癌男性及其伴侣的成本-效用分析:与常规照护的比较

Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care.
PubMed 文献 · Eur Urol Oncol · 2024-08-24

本研究从政府医疗保健视角构建10年时间跨度的马尔可夫模型,比较Navigate在线决策辅助工具与常规照护(无决策辅助)用于前列腺癌男性的成本效用。模型输入数据来自Navigate试验(n=302)及已发表研究。结果显示Navigate策略平均节省成本并产生略高的质量调整生命年(QALY),在AU$50000/QALY阈值下具有成本效用的概率为99.7%,主要由主动监测接受度和采纳率较高驱动。

要点

  • Navigate策略平均成本AU$8899(95%不确定性区间AU$7509-AU$10438),产生7.08 QALYs(95% UI 6.73-7.36)。
  • 常规照护平均成本AU$9559(95% UI AU$8177-AU$11017),产生7.03 QALYs(95% UI 6.67-7.31)。
  • Navigate策略在10年内节省成本且QALYs略高,在AU$50000/QALY阈值下具有成本效用的概率为99.7%。

核心结论

  • 在澳大利亚,针对前列腺癌男性使用在线决策辅助工具相较于常规照护似乎具有成本效用,主要由主动监测接受度和采纳率较高驱动。
  • 更广泛地实施决策辅助工具可能更好地告知被诊断前列腺癌的男性其管理选择。

研究设计与样本

  • 构建10年时间跨度的马尔可夫模型,从政府医疗保健视角进行成本-效用分析。
  • 模型输入数据来自Navigate试验(n=302)及相关已发表研究。
  • 计算两种策略的增量成本和质量调整生命年(QALY),并进行单因素和概率敏感性分析以处理模型不确定性。

主要发现

  • Navigate策略平均成本为AU$8899(95%不确定性区间AU$7509-AU$10438),产生7.08 QALYs(95% UI 6.73-7.36)。
  • 常规照护平均成本为AU$9559(95% UI AU$8177-AU$11017),产生7.03 QALYs(95% UI 6.67-7.31)。
  • Navigate策略在10年内节省成本且QALYs略高,因而优于常规照护,但两种结局的差异均较小。
  • 在传统可接受的AU$50000/QALY获得阈值下,Navigate具有成本效用的可能性为99.7%。

关键数值与推荐

  • Navigate策略平均成本AU$8899(95% UI AU$7509-AU$10438) vs 常规照护平均成本AU$9559(95% UI AU$8177-AU$11017),Navigate较常规照护节省成本。
  • Navigate策略产生7.08 QALYs(95% UI 6.73-7.36) vs 常规照护产生7.03 QALYs(95% UI 6.67-7.31),Navigate较常规照护QALYs略高。
  • 在AU$50000/QALY获得阈值下,Navigate具有成本效用的可能性为99.7%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究受限于模型所用数据的可获得性、质量和选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Evidence on the cost effectiveness of decision aids to guide management decisions for men with prostate cancer is limited. We examined the cost utility of the Navigate online decision aid for men with prostate cancer in comparison to usual care (no decision aid). METHODS: A Markov model with a 10-yr time horizon was constructed from a government health care perspective. Data from the Navigate trial (n = 302) and relevant published studies were used for model inputs. Incremental costs and quality-adjusted life-years (QALYs) were calculated for the two strategies. One-way and probabilistic sensitivity analyses were undertaken to address model uncertainty. KEY FINDINGS AND LIMITATIONS: On average, the Navigate strategy was estimated to cost AU$8899 (95% uncertainty interval [UI] AU$7509-AU$10438) and produce 7.08 QALYs (95% UI 6.73-7.36) in comparison to AU$9559 (95% UI AU$8177-AU$11017) and 7.03 QALYs (95% UI 6.67-7.31) or usual care. The Navigate strategy dominated usual care as it produced cost-savings and higher QALYs, although differences for both outcomes were small over 10 yr. The likelihood of Navigate being cost effective at a conventionally acceptable threshold of AU$50000 per QALY gained was 99.7%. This study is limited by the availability, quality, and choice of the data used in the model. CONCLUSIONS AND CLINICAL IMPLICATIONS: Use of an online decision aid for men with prostate cancer appears to be cost effective relative to usual care in Australia, driven by the higher acceptance and uptake of active surveillance. Wider implementation of decision aids may better inform men diagnosed with prostate cancer about their management options. PATIENT SUMMARY: We looked at the cost effectiveness of an online decision aid for guiding Australian men with prostate cancer in choosing a management option. We found that this decision aid was cost effective, mainly because more men chose active surveillance. Decision aids that inform patients about their management options should be more widely used in health care.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Lindsay D, Schofield P, Roberts MJ, et al. Cost-utility Analysis of Navigate, a Treatment Decision Aid for Men with Prostate Cancer and Their Partners, in Comparison to Usual Care. Eur Urol Oncol. 2024. PMID: 39181775. doi:10.1016/j.euo.2024.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。